Topics

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised

07:00 EDT 1 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Lucentis, ranibizumab, Wet Macular Degeneration,Macular Edema,Myopia, Degenerative,Diabetes Complications, Date of authorisation: 22/01/2007, Revision: 32, Status: Authorised"

Quick Search

Relevant Topic

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...